The Novel Coronavirus (nCoV)
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
This review aims to asses the actual data from recent literature dealing with the novel Coronavirus (nCoV) isolated in the automn of 2019. The nCoV has emerged in China namely in the city Wuhan (Hubei province), while the classical Coronavirus (cCoV) identified 18 years ago, came from a different region (province Guangdong). Extensive progression of nCoV represents a considerable danger for public health. The relatively great number of papers devoted to given topics in the last year (2020), also points at its importance. Despite of their non-selective acquisition, the collected data became useful for better understanding of virus replication, at description of virion structure as well as by interpretation of Coronavirus properties. Finally, the typical clinical signs of nCoV disease are briefly highlighted, not excluding the less closely related pathological states. At last but not least, relevant epidemiological data are presented when tracing the routes of nCoV spread in human population, with special regards to the region of Middle Europe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · cited 1×
“For achieving this, especially the asymptomatic COVID-19 cases should be assessed, based either on viral nucleic acid tests or on virus antigen detection [16].”
BackgroundChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
A novel coronavirus outbreak of global health concern
Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30185-9 · Cited by 7,700
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105924 · Cited by 6,068
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735 · cited 1×
“IFNalpha is a broad-spectrum antiviral substance, which has been used, to treat hepatitis B [39].”
BackgroundPresumed Asymptomatic Carrier Transmission of COVID-19
Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L., & Wang, M. (2020) · JAMA · doi:10.1001/jama.2020.2565 · Cited by 4,498
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Chan, J. F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K. K.-W., Yuan, S., & Yuen, K.-Y. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,059
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,361
Coronavirus disease 2019 (COVID-19): A literature review
Harapan, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A. L., & Mudatsir, M. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.03.019 · Cited by 1,418
Drug treatment options for the 2019-new coronavirus (2019-nCoV)
Lu, H. (2020) · BioScience Trends · doi:10.5582/bst.2020.01020 · Cited by 1,133
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · cited 2×
“(vi) A perfusion-stabilized soluble ectodomain of the given polypeptide deleted at a furin cleavage site (showing two proline mutations), and finally, the given polypeptide just with the foldon trimerization tag added: all these were assessed for their immunogenicity and protective efficacy [14,30].”
BackgroundAnti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus
Yang, Y., Sugimoto, J. D., Halloran, M. E., Basta, N. E., Chao, D. L., Matrajt, L., Potter, G., Kenah, E., & Longini, I. M. (2009) · Science · doi:10.1126/science.1177373 · Cited by 565
Favipiravir: A new and emerging antiviral option in COVID-19
Agrawal, U., Raju, R., & Udwadia, Z. F. (2020) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2020.08.004 · Cited by 390
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Garvin, M. R., Alvarez, C., Miller, J. I., Prates, E. T., Walker, A. M., Amos, B. K., Mast, A. E., Justice, A., Aronow, B., & Jacobson, D. (2020) · eLife · doi:10.7554/elife.59177 · Cited by 361
Arendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV
Lee, P.-I., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.02.001 · Cited by 327
Outbreak of 2009 Pandemic Influenza A (H1N1) at a New York City School
Lessler, J., Reich, N. G., & Cummings, D. A. T. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906089 · Cited by 308
Yang, X.-L., Hu, B., Wang, B., Wang, M.-N., Zhang, Q., Zhang, W., Wu, L.-J., Ge, X.-Y., Zhang, Y.-Z., Daszak, P., et al. (2016) · Journal of Virology · doi:10.1128/jvi.02582-15 · Cited by 249
CORONAVIRUS DISEASE 2019 (COVID-19): A LITERATURE REVIEW
Ibrahim, B., & Önem, E. (2021) · Gevher Nesibe Journal IESDR · doi:10.46648/gnj.200 · Cited by 239
An interim review of the epidemiological characteristics of 2019 novel coronavirus
Ryu, S., & Chun, B. C. (2020) · Epidemiology and Health · doi:10.4178/epih.e2020006 · Cited by 198
Dhama, K., Patel, S. K., Pathak, M., Yatoo, M. I., Tiwari, R., Malik, Y. S., Singh, R., Sah, R., Rabaan, A. A., Bonilla-Aldana, D. K., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101755 · Cited by 192
A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan
Liu, Y.-C., Liao, C.-H., Chang, C.-F., Chou, C.-C., & Lin, Y. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001573 · Cited by 157
Nishiura, H., Linton, N. M., & Akhmetzhanov, A. R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020488 · Cited by 136
Li, R., Qiao, S., & Zhang, G. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.02.013 · Cited by 125
Goh, G. K., Dunker, A. K., Foster, J. A., & Uversky, V. N. (2020) · Biomolecules · doi:10.3390/biom10020331 · Cited by 69
Blood Pressure and the Renal Actions of AT2 Receptors
Carey, R. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0720-7 · Cited by 28
García‐Salido, A. (2020) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2020.04.006 · Cited by 13
Cited by
Sohrabi, C., Alsafi, Z., O'Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., Iosifidis, C., & Agha, R. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.02.034 · Cited by 6,069
SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat
Zheng, J. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45053 · Cited by 1,025
Acter, T., Uddin, N., Das, J., Akhter, A., Choudhury, T. R., & Kim, S. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2020.138996 · Cited by 575
Potential impact of seasonal forcing on a SARS-CoV-2 pandemic
Neher, R. A., Dyrdak, R., Druelle, V., Hodcroft, E. B., & Albert, J. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20224 · Cited by 286
Association between 2019-nCoV transmission and N95 respirator use
(2020) · doi:10.1016/j.jhin.2020.02.021 · Cited by 213
Metadata
- Authors
- RajÄáni, J.
- Venue
- Microbiology & Infectious Diseases
- Publisher
- SciVision Publishers LLC
- Published
- 2021-06-30
- Volume
- 5
- Issue
- 3
- ISSN
- 2639-9458 (ISSN-L)
- OpenAlex
- W4210732633
- Cited by
- 303
- References
- 36
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.